Skip Navigation



Schizophrenia Bulletin Advance Access published online on July 7, 2007
Schizophrenia Bulletin, doi:10.1093/schbul/sbm077
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
33/5/1156    most recent
sbm077v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Geyer, M. A.
Right arrow Articles by Tamminga, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geyer, M. A.
Right arrow Articles by Tamminga, C. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.

Wayne Fenton's Impact on Academic Neuroscience

Mark A. Geyer1,2 and Carol A. Tamminga3
2 Department of Psychiatry, University of California San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0804
3 University of Texas Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, TX 75390

1 To whom correspondence should be addressed; tel: 619-543-3582, fax: 619-543-2493, e-mail: mgeyer{at}ucsd.edu.

The legacy of Wayne Fenton will undoubtedly include his broad impact upon the academic community of researchers in psychiatry and neuroscience. Although this impact has already been felt, its full breadth and depth can only be anticipated. Eventually, the most profound impact of Wayne Fenton's legacy will likely be the one Wayne most fervently desired: that people with psychiatric disorders receive better and more effective treatments for their illnesses. By virtue of the MATRICS initiative, this impact will begin in the context of treatments for the cognitive deficits in schizophrenia, which is currently a critical unmet need. Within academic settings, this specific impact is already evident as a resurgence of interest in the neurobiology and pharmacology relevant to cognitive dysfunction in schizophrenia. As envisioned by Wayne Fenton, however, the impact of MATRICS and the other programs he initiated will be broader than "only" the treatment of cognitive deficits in schizophrenia. His vision was to target a drug treatment to an individual symptom domain, individualizing treatment regimens for each patient, without requiring a drug to be effective in all domains. Thus, the particular target of opportunity that provided Wayne Fenton's focus in the initiation of the MATRICS program is already having an important impact, but in the longer term these efforts will no doubt lead to parallel developments and improvements in the treatment of other psychiatric disorders.

Keywords: MATRICS / schizophrenia / cognition


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.